Real-world observational study of current treatment patterns and outcomes in recurrent or locally advanced/metastatic non-small cell lung cancer
Real-world observational study of current treatment patterns and outcomes in recurrent or locally advanced/metastatic non-small cell lung cancer
Blog Article
Background: Treatment for recurrent or advanced/metastatic non-small cell lung cancer (aNSCLC) has advanced in the past 5 years with immunotherapy (IO).This study sought to describe first-line (1L) aNSCLC treatment patterns and clinical outcomes.Methods: In this retrospective, multisite cohort study, community oncologists reported data for randomly selected stage IIIB/IV, EGFR-/ALK wild-type aNSCLC patients who initiated 1L deus gorras systemic therapy from 01/01/2016 to 12/31/2019.Follow-up was through November 2020.
Demographics, clinical characteristics, treatment patterns, disease response, progression, and death/last follow-up date were described.Overall response rate (ORR) was calculated using tumor measurements applying RECIST v1.1 guidelines.Progression-free survival (PFS) and overall survival (OS) were calculated from 1L initiation by Kaplan-Meier method.
Results: 497 patients from 46 sites were included.The most common 1L regimens (%) were platinum-doublet chemotherapy plus IO (PDC+IO) (40.6%), PDC (29.4%), IO monotherapy (20.
7%), and PDC+bevacizumab (6.2%).From 2016 to 2019, 1L PDC declined from 63% to 10%, whereas 1L PDC+IO click here increased from 14% to 58%.The ORRs were 64.
9%, 32.9%, 60.2%, and 61.3% for 1L PDC+IO, PDC, IO monotherapy, and PDC+bevacizumab, respectively.
Median 1L PFS/OS (months) was 15.6/26.5, 5.3/13.
7, 17.8/not reached, 10.8/18.6, respectively, for PDC+IO, PDC, IO monotherapy, and PDC+bevacizumab.
Among patients who received only 1L treatment (n = 299), 41.5% had no further therapy and were deceased.Conclusions: Although the 1L treatment paradigm has recently shifted to IO-based regimens, 41.5% did not survive past 1L.
Median 1L PFS did not exceed 1.5 years and median OS remained limited across all 1L treatment groups, illustrating continued unmet aNSCLC therapeutic needs.